{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-006027","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.617319+00:00","generated_at":"2026-05-17T05:53:15.592262+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader","bullets":["Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.","FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.","SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.","BeyondSpring expects to continue consolidating SEED as it retains substantive control."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-006027","json":"https://secwatch.observer/filing/0001171843-25-006027.json","markdown":"https://secwatch.observer/filing/0001171843-25-006027.md","text":"https://secwatch.observer/filing/0001171843-25-006027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/0001171843-25-006027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/f8k_092225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:53:15.592262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}